Blessing for the Bleeder: Bevacizumab in Hereditary Hemorrhagic Telangiectasia

Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by uncontrolled multisystem angiogenesis with epistaxis, gastrointestinal bleeding, iron-deficiency anemia, and arteriovenous malformations, and is often associated with increased levels of vascular endothelial growth factor (VEGF). Bevacizumab, a VEGF inhibitor, reduces epistaxis, telangiectasias, and iron-deficiency anemia. We present the case of a woman with HHT and chronic gastrointestinal bleeding who required iron supplementation and multiple blood transfusions. Bevacizumab resulted in marked symptom improvement and transfusion-independence. Our report describes the dose schedule and calls for a randomized, controlled trial demonstrating the value of bevacizumab therapy.

[1]  J. Saurin,et al.  Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. , 2012, JAMA.

[2]  C. Freter,et al.  Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab. , 2012, The American journal of the medical sciences.

[3]  Z. Ge,et al.  Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. , 2011, Gastroenterology.

[4]  N. Choong,et al.  Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. , 2011, The New England journal of medicine.

[5]  S. Dheyauldeen,et al.  Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia , 2010, Annals of Hematology.

[6]  J. Holter,et al.  Bevacizumab in hereditary hemorrhagic telangiectasia. , 2009, The New England journal of medicine.

[7]  S. Oosting,et al.  More on bevacizumab in hereditary hemorrhagic telangiectasia. , 2009, The New England journal of medicine.

[8]  L. Adams,et al.  Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[9]  L. David,et al.  Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. , 2007, Blood.

[10]  W. Fischbach,et al.  Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab , 2006, Annals of Hematology.

[11]  H. Blau,et al.  VEGF gene delivery to myocardium: deleterious effects of unregulated expression. , 2000, Circulation.

[12]  A. Guttmacher,et al.  Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). , 2000, American journal of medical genetics.

[13]  D. W. Johnson,et al.  Mutations in the activin receptor–like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2 , 1996, Nature Genetics.

[14]  K. Hörmann,et al.  Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. , 2005, Haematologica.

[15]  D. W. Johnson,et al.  Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 , 1994, Nature Genetics.

[16]  H. Uchino,et al.  DEPARTMENT OF INTERNAL MEDICINE , 1966 .